Lipid nanoparticle-mediated CRISPR/Cas9 delivery enables efficient trabecular meshwork gene editing in mice
Year: 2025
Type: article
Abstract: Lipid nanoparticles (LNPs) enable efficient mRNA delivery, yet their potential for ocular gene editing remains largely unexplored. Here, we systematically evaluated three LNP formulations containing distinct ionizable lipids, DLin-MC3-DMA, ALC0315, and SM102, for gene delivery to ocular tissues. Among them, SM102-based LNP encapsulating GFP mRNA (SM102-GFP) exhibited the highest transfection efficiency across three cultured ocular cells in vitro. Following intravitreal injection in mice, SM102-GFP achieved selective and robust expression in the trabecular meshwork (TM) without detectable retinal transfection. GFP expression in TM peaked at one week post-injection, declined by three weeks, and could be effectively re-induced by a second dosing of the same vector. Compared with adeno-associated viral (AAV) and adenoviral (Ad) vectors, SM102-GFP showed superior TM specificity and reduced retinal inflammation. Co-delivery of SpCas9 mRNA and sgRNA via SM102-based LNPs enabled efficient CRISPR-mediated knockout of Matrix Gla Protein (Mgp), a key inhibitor of TM calcification. Mgp knockout induced sustained intraocular pressure elevation and anterior chamber deepening with open angles, recapitulating features of primary open-angle glaucoma. Chronic ocular hypertension further led to Müller gliosis and ganglion cell complex thinning, indicative of progressive retinal stress. These findings establish SM102-based LNPs as a safe and efficient platform for TM-targeted gene editing and glaucoma modeling.
Source: Journal of Controlled Release
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,440
Funders: Tulane University, Research Grants Council, University Grants Committee, Innovation and Technology Commission, Hong Kong Polytechnic University, Food and Health Bureau, Innovation and Technology Fund, Science, Technology and Innovation Commission of Shenzhen Municipality, University of Oklahoma Health Sciences Center, Health and Medical Research Fund, Shenzhen Science and Technology Innovation Program
Awards: Unlock the regenerative capacity of Müller glia in mammalian retinas by Wnt/p27kip1 signaling, Development of A Non-viral Gene Therapy Platform for Retinal Degenerative Diseases, Development of A Non-viral Gene Therapy Platform for Retinal Degenerative Diseases, A gene therapy approach to stimulate retinal regeneration by targeted expression of Atoh7, G5754723808
OpenAlex ID: W4416918882
